Evidence map›Paper›PMID 34897154›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.

Takeshi Hatanaka, Satoru Kakizaki, Takuya Kaburagi, Naoto Saito, Sachi Nakano, Yoichi Hazama, Sachiko Yoshida, Yoko Hachisu, Yoshiki Tanaka, Teruo Yoshinaga and 9 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Satoru KakizakiDepartment of Clinical Research, National Hospital Organization Takasaki General Medical Center, Japan.
Takuya KaburagiDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Naoto SaitoDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Sachi NakanoDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Yoichi HazamaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Sachiko YoshidaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Yoko HachisuDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Yoshiki TanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Teruo YoshinagaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan.
Kenji KashiwabaraDepartment of Pathology, Gunma Saiseikai Maebashi Hospital, Japan.
Atsushi NaganumaDepartment of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan.
Yuichi YamazakiDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Toshio UraokaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Shigeo NagashimaDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan.
Masaharu TakahashiDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan.
Tsutomu NishizawaDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan.
Kazumoto MurataDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan.
Hiroaki OkamotoDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan.
Gunma Saiseikai Maebashi Hospital · JPJichi Medical University · JPGunma University · JPNational Hospital Organization Takasaki Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 66-year-old man, who had undergone plasma exchange 30 years previously in Egypt for the treatment of falciparum malaria, was referred to our hospital for treatment of chronic hepatitis C (HCV). An analysis of the 655-nucleotide 5'-untranslated region-core region sequence revealed infection with HCV subtype 1g. A phylogenetic analysis of the full-length HCV genome confirmed that the patient's HCV was subtype 1g, which was the first case identified in Japan. Although his HCV possessed several naturally occurring resistance-associated substitutions in the nonstructural (NS) 3 and NS5A regions, he was successfully treated by combination therapy with glecaprevir/pibrentasvir.

Indexed as

HepacivirusHepatitis C, ChronicAgedAminoisobutyric AcidsAntiviral AgentsBenzimidazolesCyclopropanesDrug CombinationsGenotypeHumansJapanLactams, MacrocyclicLeucineMalePersistent InfectionPhylogenyAminoisobutyric AcidsAntiviral AgentsBenzimidazolesCyclopropanesDrug CombinationsglecaprevirLactams, MacrocyclicLeucinepibrentasvirProlinePyrrolidinesQuinoxalinesSulfonamidesglecaprevir/pibrentasvirhepatitis C virussubtype 1g

Identifiers

PMID34897154
PMCPMC9177357
OpenAlexW4200006415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.